Basic Information
| LncRNA/CircRNA Name | lncRNA-PDPK2P |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | Microarray, qPCR, Western blot, RIP |
| Sample | The normal LO2 hepatocytes and hepatocellular carcinoma cell lines (MHCC -97L, HCC -97H, BEL -7404, HCCLM3, SMMC -7721), Hep3B and HepG2 cell lines, HCC and adjacent tissues |
| Expression Pattern | up-regulated |
| Function Description | lncRNA-PDPK2P was highly expressed in HCC tissues with a distinct positive correlation between PDPK2P and PDK1, and the upregulation was clinically associated with a larger tumor embolus, low differentiation and poor survival. Mechanistically, lncRNA-PDPK2P interacted with PDK1, and promoted HCC progression through the PDK1/AKT/caspase 3 signaling pathway. lncRNA-PDPK2P can promote HCC progression, suggesting it may be a clinically valuable biomarker and serve as a molecular target for the diagnosis, prognosis and therapy of hepatocellular carcinoma. |
| Pubmed ID | 31368655 |
| Year | 2019 |
| Title | lncRNA -PDPK2P promotes hepatocellular carcinoma progression through the PDK1/AKT/Caspase 3 pathway |
External Links
| Links for lncRNA-PDPK2P | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |